Women of color and HIV/AIDS: Epidemiology, clinical aspects, and management

HIV/AIDS in U.S. Communities of Color

Volumn , Issue , 2009, Pages 83-101

  Ojikutu, Bisola O ^a   Stone, Valerie E ^a   Bardeguez, Arlene ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053133140     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-98152-9_6     Document Type: Chapter

References (126)

1. Centers for Disease Control and Prevention (CDC). HIV/AIDS Surveillance Report. 2005;17:1-54.
2. Centers for Disease Control and Prevention (CDC). Racial/ethnic disparities in diagnoses of HIV/AIDS-33 states, 2001-2005. MMWR Weekly Report. 2007;56:189-193.
3. Adimora AA, Schoenbach VJ, Martinson FE, et al. Social context of sexual relationships among rural African Americans. Sex Trans Dis. 2001;28:69-76.
4. Moreno CL, El-Bassel N,Morrill AC. Heterosexual women of color and HIV risk: sexual risk factors for HIV among Latina and African American women. Women Health. 2007;45:1-15.
5. Forna FM, Fitzpatrick L, Adimora AA. A case-control study of factors associated with HIV infection among black women. J Natl Med Assoc. 2006;98(11):1798-804.
6. UNAIDS and World Health Organization. AIDS Epidemic Update. December 2007. Available at: http://data.unaids.org/pub/EPISlides/2007/2007 epiupdate en.pdf. Accessed: January 15, 2008.
7. Ginzburg HM, Fleming PL, Miller KD. Selected public health observations derived from Multicenter AIDS Cohort Study. JAIDS. 1988;1:2-7.
8. Ledergerber B, von Overbeck J, Egger M. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. Soz Praentivmed.1994;39:387-94.
9. Barkan S, Melnick S, Preston-Martin S. The Women's interagency HIV Study. Epidemiology. 1998;9:117-125.
10. Smith DK, Warren DL, Vlahov D. Design and baseline participant characteristics of the Human Immunodeficiency Virus Epidemiology Research (HER) Study: a prospective cohort study of human immunodeficiency virus infection in U.S. women. Am J Epidemiol. 1997;146:459-69.
11. Hader S, Smith DK, Moore JS, et al. HIV Infection in Women in the United States: status at the Millennium JAMA. 2001;9:1186-92.
12. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ. 1992;304:809-813.
13. Mastro TD, de Vincezzi I. Probabilities of sexual HIV transmission. AIDS. 1996;10(Suppl A):S75-82.
14. Vittinghoff E, Douglas J, Judson F, et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol. 1999;150:306-11.
15. Jaffe LR, Seehaus M, Wagner C, et al. Anal intercourse and knowledge of acquired immunodeficiency syndrome among minority-group female adolescents. J Pediatr. 1988;112: 1005-7.
16. Houston AM, Fang J, Husman C, et al. More than just vaginal intercourse: anal intercourse and condom use patterns in the context of "main" and "casual" sexual relationships among urban minority adolescent females. J Pediatr Adolesc Gynecol. 2007;20:299-304.
17. Lifson AR, O'Malley PM, Hessol NA, et al. HIV seroconversion in two homosexual men after receptive oral intercourse with ejaculation: implications for counseling concerning safe sexual practices. Am J Public Health. 1990;80:1509-11.
18. Rothenberg RB, ScarlettM, del Rio C, et al. Oral Transmission of HIV. AIDS 1998;12:2095-2105.
19. Rich JD, Buck A, Tuomala RE, et al. Transmission of human immunodeficiency virus infection presumed to have occurred via female homosexual contact. Clin Infect Dis. 1993;17:1003-5.
20. Kwakwa HA, Ghobrial MW. Female-to-female transmission of human immunodeficiency virus. Clin Infect Dis. 2003;36(3):e40-1. Epub 2003 Jan 10.
21. Sarkar K, Bai B, Mukherjee R, et al. Young age is a risk factor for HIV among female sex workers-An experience from India. J Infect. 2006;53:4;255-259.
22. Bulterys M, Chao A, Habimana P, et al. Incident HIV-1 infection in a cohort of young women in Butare, Rwanda. AIDS 1994;8:1585-1591.
23. Moscicki AB, Ma Y, Holland C, et al. Cervical ectopy in adolescent girls with and without human immunodeficiency virus infection. J Infect Dis. 2001;183:865-70.
24. Moss GB, Clemetson D, D'Costa L, et al. Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results of a study of couples in Nairobi, Kenya. J Infect Dis. 1991;164:588-91.
25. Heffernan R, Chiasson MA, Sackoff JE. HIV risk behaviors among adolescents at a sexually transmitted disease clinic in New York City. J Adolesc Health. 1996;18:429-34.
26. Clark RA, Kissinger P, Bedimo AL, et al. Determination of factors associated with condom use among women infected with human immunodeficiency virus. Int J STD AIDS. 1997;8:229-33.
27. Fleming DT,Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75:3-17.
28. Hanson J, Posner S, Hassig S, et al. Assessment of sexually transmitted diseases as risk factors for HIV seroconversion in a New Orleans sexually transmitted disease clinic, 1990- 1998. Ann Epidemiol. 2005;15:13-20.
29. Xu F, Sternberg MR, Kottri BJ, et al. Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States. JAMA. 2006;296:964-973.
30. Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007;370:2127-37.
31. Centers for Disease Control and Prevention. Health Disparities in HIV/AIDS, Viral Hepatitis, Sexually Transmitted Disease and Tuberculosis in the United States. Available at: http://www.cdc.gov/NCHHSTP/healthdisparities/docs/ NCHHSTPHealthDisparitiesReport1107. pdf. Accessed: February 3, 2008.
32. Ragni MV, Faruki H, Kingsley LA. Heterosexual HIV-1 transmission and viral load in hemophilic patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:42-5.
33. Pedraza MA, Del Romero J, Roldan F, et al. Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr. 1999;2:120-5.
34. Tanfer K, Aral SO. Sexual intercourse during menstruation and self-reported sexually transmitted disease history among women. Sex Transm Dis. 1996;23:395-40.
35. Guimaraes MD, Vlahov D, Castilho EA. Postcoital vaginal bleeding as a risk factor for transmission of the human immunodeficiency virus in a heterosexual partner study in Brazil. Rio de Janeiro Heterosexual Study Group. Arch Intern Med. 1997;157:1362-8.
36. Baeten JM, Nyange PM, Richardson BA, et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol. 2001;185:380-5.
37. Moss GB, Clemetson D, D'Costa L, et al. Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results of a study of couples in Nairobi, Kenya. J Infect Dis. 1991;164:588-91.
38. Ghanem KG, Shah N, Klein RS, et al. Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. J Infect Dis. 2005;191:358-66.
39. Prakash M, Kapembwa MS, Gotch F, et al. Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4(+) T cells in the cervical epithelium of healthy women. J Reprod Immunol. 2002;54:117-31.
40. Kapiga SH, Lyamuya EF, Lwihula GK. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS. 1998;12:75-84.
41. Daly CC, Helling-Giese GE, Mati JK. Contraceptive methods and the transmission of HIV: implications for family planning. Genitourin Med. 1994;70:110-7.
42. Meirik O. Intrauterine devices - upper and lower genital tract infections. Contraception. 2007;75(Suppl 6):S41-7.
43. Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197:144.e1-8.
44. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use and progression of human immunodeficiency disease. N Eng J Med. 1995;331:751-6.
45. Melnick SL, Sherer R, Louis TA, et al. Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA. 1994;2727:1915-21.
46. Squires K. Gender difference in the diagnosis and treatment of HIV. Gend Med. 2007;4:294-307.
47. Levine RS, Briggs NC, Kilbourn BS. Black-white mortality from HIV in the United States before and after introduction of highly active antiretroviral therapy in 1996. AmJ Pub Health. 2007;97:1884-92.
48. Gebo KA, Fleishan JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquire Immune Defic Syndr. 2005;38:96-103.
49. Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001;344:720-5.
50. Panel on Antiretroviral Therapy Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescent. Department of Health and Human Services. January 29, 2008;1-128. Available: http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf. Accessed on July 12, 2008.
51. Cooley TP, Hirschhorn LR, O'Keane JC. Kaposi's sarcoma in women with AIDS. AIDS. 1996;10:1221-5.
52. Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States From 1973 through 1998. J Natl Cancer Inst. 2002;94:1204-1210.
53. Nasti G, Serraino D, Ridolfo, A, et al. AIDS-Associated Kaposi's Sarcoma Is More Aggressive in Women: A Study of 54 Patients. AIDS. 1999;20:337-341
54. Meditz AL; Borok M; MaWhinney S, et al. Gender differences in AIDS-associated Kaposi sarcoma in Harare, Zimbabwe. J Acquir Immune Defic Syndr.2007; 44:306-308.
55. Engels E; Pfeiffer RM; Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS. 2006;20:1645-1654.
56. Frisch M, Biggar RJ, Engels E, et al. Association of cancer with AIDS-related immunosuppression in adults.JAMA. 2001;285:1736-1745.
57. Kirk GD, Merlo C, Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45:103-10.
58. Goedert JJ, Schainer C, McNeel TS, et al. Risk of breast, ovary, and uterine corpus cancers among 85 268 women with AIDS. Br J Cancer. 2006;95:642-648.
59. Frisch M, Biggar RJ, and Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;4;285:1736-45.
60. Herida M, Mary Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003;15;21:3447-53.
61. Morris A, Lundgren JD, Masur H, et al. Current epidemiology of pneumocystis pneumonia. Emerg Infect Dis. 2004;10:1713-1720.
62. Kaplan JE, Hanson DL, Navin TR, et al. Risk factors for Pneumocystis carinii pneumonia in human immunodeficiency virus infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J Infect Dis. 1998;178:1126-32.
63. Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Study Group. AM J Respir Crit Care Med. 1997;155:60-6.
64. Chan IS, Neaton JD, Saravolatz LD, et al. Frequencies of opportunistic diseases prior to death among HIV-infected persons. Community Programs for Clinical Research on AIDS. AIDS. 1995;9:1145-51.
65. Jones JL, Hanson DL, Dworkin MS, et al. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. MMWR CDC Surveill Summ. 1999;48:1-22.
66. Wills TS, Nadler JP, Somboonwit C, et al. Anemia prevalence and associated risk factors in a single-center ambulatory HIV clinical cohort. AIDS Read. 2004;14:305-10, 313-5.
67. Semba RD. Iron-deficiency anemia and the cycle of poverty among human immunodeficiency virus-infected women in the inner city. Source: Clin Infect Dis. 2003;37(Suppl 1) 2-11.
68. Sullivan PS, Hanson DL, Chu SY, et al. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood. 1998;91:301-8.
69. Sullivan PS, Hanson DL, Chu SY, et al. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate adult and adolescent spectrum of disease project. JAIDS. 1997;14:374-9.
70. Cu-Uvin, S Hogan JW, Warren D, et al. Prevalence of lower genital tract infection among HIV-seropositive and high risk seronegative women. HIV Epidemiology Research Study (HERS) Group. Clin Infect Dis. 1999;29:1145-1150.
71. Minkoff HL, Eisenberger-Matityahu D, Fedman J, et al. Prevalence and incidence of gynecologic disorders among women infected with human immunodeficiency virus. Am J Obstet Gynecol. 1999;180:824-836.
72. Frankel RE, Selwyn PA, Mexger J, Andrews S. High prevalence of gynecologic disease among hospitalized women with human immunodeficiency virus infection. Clin Infect Dis. 1997;25:706-712.
73. Duerr A, Heilig CM, Meikle SF, et al. Incident and persisistent vulvovaginal candidiasis among human immunodeficiency virus infected women: risk factors and severity. Obstet Gynecol. 2003;101:548-556.
74. Irwin KL, Moorman AC, O'Sullivan MJ, et al. Influence of Human Immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol. 2000;95:525-34.
75. Harlow SD, Cohen M, Ohmit SE, Schuman P, Cu-Uvin S, Lin X, et al. Substance abuse and psychotherapeutic medications: a likely contributor to menstrual disorders in women who are seropositive for human immunodeficiency virus. Am J Obstet Gynecol. 2003;188:991-996.
76. Cu-Uvin S, Hogan JW, Caliendo AM, et al. HIV Epidemiology Research Study (HERS) Group. Association between bacterial vaginosis and expression of Human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis. 1999;29:1145-1150.
77. Greenblatt RM, Bacchetti P, Barkan S, et al. Lower genital tract infections among HIVinfected and high risk uninfected women: findings of the Womens' Interagency HIV Study (WIHS) Sex Transm Dis. 1999;26:143-151.
78. Sutton M, Sternberg M, Koumans EH. The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001-2004. CID. 2007;45:1319-26.
79. Van Der Pol B, Kwolk C, Pierre-Louis B, et al. Trichomonas vaginalis infection and human immunodeficiency virus acquisition in African women. JID. 2008;197:548-54.
80. Miller M, Liao Y, Gomez AM, et al. Factors associated with the prevalence and incidence of Trichomonas vaginalis infection among African American women in New York city who used drugs. JID. 2008;197:503-9.
81. Cu-Uvin S, Ko H, Jamieson DJ, et al. Prevalence, incidence and persistence or recurrence of trichomonasis among HIV-positive women and among HIV negative women at high risk for HIV infection. Clin Infect Dis. 2002;34:406-11.
82. Aberg JA, Gallant JE, Anderson J, Oleske JM, Libman H, Currier JS, Stone VE, Kaplan JE. Primary care guidelines for the management of persons infected with human immunodeficiency virus: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America. Clin Infect Dis. 2009; in press.
83. Xu F, Schillinger JA, Sternberg MR, et al. Seroprevalence and co-infection with Herpes simplex virus type 1 and type 2 in the U.S., 1988-1994. J Infect Dis. 2002;185:1019-1024.
84. Heng M, Heng S, Allen S. Coinfection and synergy of HIV-1 and HSV. Lancet. 1994; 343:255-258.
85. Little SE, Caughey AB. Acyclovir prophylaxis for pregnant women with a known history of herpes simplex virus: A cost-effectiveness analysis. Am J Obstet Gynecol. 2005;193:1274-9.
86. Brown ZA, Gardlla C, Wald A, et al. Genital Herpes Complicating Pregnancy. Obstet Gynecol. 2005;106(4):845-56.
87. Sheffield JS, Hill JB, Hollier LM, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery. A randomized clinical trial. Obstet Gynecol. 2006;108:141-7.
88. Chen KT, Segu M, Lumey LH, et al. Genital herpes virus infection and perinatal transmission of Human Immunodeficiency Virus. Obstet Gynecol. 2005;106:1341-8.
89. Herad I, Tassie J, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G. Increased Risk of Cervical Disease Among Human Immunodeficiency Virus-Infected Women with severe Immunosuppression and High Human Papillomavirus Load. Obstet Gynecol. 2000;96: 403-9.
90. Stratton P, Gupta P, Riester K. Cervical dysplasia on cerivcovaginal papanicolaou smear among HIV-1-infected pregnant and non-pregnant women. JAIDS. 1999;20(3):300-307.
91. Klein RS, Ho GYF, Vermund SH, Fleming I, Burk RD. Risk factors for squamous intraepithelial lesions on pap smear in women at risk for human immunodeficiency virus infection. J Infec Dis. 1994;170:1404-9.
92. Stanberry LR, Rosenthal SL, Mills L, et al. Longitudinal risk of herpes simplex virus (HSV) type 1, HSV type 2, and cytomegalovirus infections among young adolescent girls. CID. 2004;39:1433-8.
93. Massad LS, Riester KA, Anatos KM. Prevalence and predictors of squamous cell Abnormalities in Papanicolaou Smears from Women Infected with HIV-1. JAIDS. 1999;21(1):33-41.
94. Delmas M, Larsen C, van Benthem B, et al. Cervical squamous intraepithelial lesions in HIV-infected women: prevalence, incidence and regression. AIDS. 2000;14:1775-1784.
95. Wright TC, Massad LS, Dunton C, et al. for the 2006 American Society for Colposcopy and Cervical pathology (ASCCP) Sponsored Consensus Conference. 2006 Consensus Guidelines for the Management of Women with abnormal cervical cancer screening tests. Am L Obstet Gynecol. 2007;197:340-355.
96. Saraiya M, Ahmed F, Krishnan S, et al. Cervical cancer Incidence in a Prevaccine era in the United States, 1998-2002. Obstet Gynecol. 2007;109:360-70.
97. Wallin K, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999;341:1633-8.
98. Human Papillomavirus Vaccination. ACOG Committee Opinion Number 344, September 2006. Obstet Gynecol. 2006;108:699-705.
99. Benard VB, Coughlin SS, Thompson T, et al. Cervical cancer incidence in the United States by area of residence, 1998-2001. Obstet Gynecol. 2007;110:681-6.
100. Jones RW, Rowan DM, Stewart AW. Vulvar Epithelial Neoplasia. Obstet Gynecol. 2005;106:1319-26.
101. Conley LJ, Ellerbrock TV, Bush TJ. HIV infection and risk of Vulvovaginal and Perianal Condylomata Accuminata and Intraepithelial Neoplasia: A prospective cohort study. Lancet 2002;359:108-13.
102. Taube JM, Nichols AD, Bornman DM, et al. Langerhans cell density and high grade vulvar intraepithelial neoplasia in women with human immunodeficiency virus infection. J Cutan Pathol. 2007;34:565-70.
103. Elit L, Voruganti S, Simunovic M. Invasive vulvar cancer in a women with human immunodeficiency virus: Case report and review of the literature. Gynecol Oncol. 2005;98:151-4.
104. Jamieson D, Paramsothy P, Cu-Uvin S, et al. for the HIV Epidemiology Research Study Group. Vulvar, vaginal, and Perineal Intraepithelial Neoplasia in women with or at risk for Human immunodeficiency Virus. Obstet Gynecol. 2006;107:1023-8.
105. Cohn SE, Park J-G, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy:Effective contraception and lack of clinically significant interactions. Nature.com. 2007;81(2):222-2227.
106. Steiner MJ, Kwok C, dominik R, et al. Pregnancy risk among oral contraceptive pill, injectable contraceptive, and condom users in Uganda, Zimbabwe, and Thailand. Obstet Gynecol. 2007;110:1003-9.
107. Stinger EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive devise versus hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197:144.e1-144.e8.
108. Baeten JM, Lavreys L, Overbaugh J. The influence of hormonal contraceptive use on HIV-1 transmission and Disease progression. CID. 2007;45:360-9.
109. Peterson HB Sterilization Obstet Gynecol. 2008;111(1):189-202.
110. El-Sadr W, Gelttler J. Unrecognized Human Immuno-deficiency virus infection in the elderly. Arch Intern Med. 1995;155:184-86.
111. Centers for Disease Control and Prevention, HIV/AIDS Surveillance Report. 2006;18:1-56.
112. Cejtin HE. Gynecologic issues in the HIV-infected woman. Obstet Gynecol Clin North Am. 2003;30(4):711-29.
113. Santoro N, Arsten JH, Buono D, et al. Impact of street drug use, HIV infection, and highly active antiretroviral therapy on reproductive hormones in middle-aged women. J Womens Health (Larchmt). 2005;14:898-905.
114. Fantry LE, Zhan M, Taylor GH, et al. Age of menopause and menopausal symptoms in HIV-infected women. AIDS Patient Care STDs. 2005;19:703-711.
115. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. 2005;16:1345-52. Epub 2005 March 8.
116. Washington DL, Bowles J, Saha S, et al. Transforming clinical practice to eliminate racialethnic disparities in healthcare. J Gen Intern Med. 2008;23(5):685-91.
117. Angelino A,Willard S. The need for sociocultural awaremness to maximize treatment acceptance and adherence in individuals initiating HIV therapy. J Int Assoc Physicians AIDS Care. 2008;7(Suppl 1):S17-S21.
118. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States. JAMA. 1999;281:2305-2315.
119. Gebo KA, Fleishman JA, Conviser R, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr. 2005;38(1):96-103.
120. Cohen MH, Cook JA, Grey D, et al. Medically eligible women who do not use HAART: The importance of abuse, drug use, and race. AM J Pub Health. 2004;94(7):1147-1151.
121. Hirschhorn LR, Boswell SL, Stone VE. Discontinuation (D/C) of Protease Inhibitor (PI) Therapy: Reasons and Risk Factors. Presented at the 12th World AIDS Conference, Geneva Switzerland, June 28-July 3, 1998.
122. Losina E, Schackman B, Sadownik S, et al. Disparities in survival attributable to suboptimal HIV care in the U.S.: influence of gender and race/ethnicity [Abstract #142]. Paper Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA: February 25-28, 2007.
123. Malcolm SE, Ng JJ, Rosen RK, Stone VE. An examination of HIV/AIDS patients who have excellent adherence to HAART. AIDS Care. 2003;15:251-61.
124. Stone VE, Clarke J, Lovell J, et al. HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med. 1998;13(9):586-593.
125. Stone VE, Weissman JS, Cleary P. Satisfaction with ambulatory care of persons with AIDS: Predictors of patient ratings of quality. J Gen Intern Med. 1995;10:239-245.
126. SteinMD, Fleishman J,Mor V, DresserM. Factors associated with patient satisfaction among symptomatic HIV-infected persons. Med Care. 1993;31:182-88.